Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   40165   clinical trials with a EudraCT protocol, of which   6574   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2016-003069-25
    Sponsor's Protocol Code Number:DSE-EDO-01-16-EU
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2017-02-01
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2016-003069-25
    A.3Full title of the trial
    A Prospective, Randomized, Open-Label, Blinded Endpoint Evaluation (PROBE) Parallel Group Study Comparing Edoxaban vs. VKA in Subjects Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation (ELIMINATE-AF)
    Estudio prospectivo, aleatorizado, abierto, con evaluación ciega de las variables (PROBE) y de grupos paralelos para comparar edoxabán frente a antagonistas de la vitamina K (AVK) en pacientes que se someten a ablación con catéter de la fibrilación auricular no valvular (ELIMINATE-AF)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Edoxaban treatment versus anticoagulant treatment (here Vitamin K antagonist) in patients with atrial fibrilation undergoing a catheter ablation
    Tratamiento con Edoxaban versus tratamiento anticoagulante (aquí antagonista de la Vitamina K) en pacientes con fibrilación auricular sometidos a ablación con catéter
    A.3.2Name or abbreviated title of the trial where available
    ELIMINATE-AF
    A.4.1Sponsor's protocol code numberDSE-EDO-01-16-EU
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorDaiichi Sankyo Europe GmbH
    B.1.3.4CountryGermany
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportDaiichi Sankyo Europe GmbH
    B.4.2CountryGermany
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationDaiichi Sankyo Europe GmbH
    B.5.2Functional name of contact pointLate Phase Clinical Operations
    B.5.3 Address:
    B.5.3.1Street AddressZielstattstrasse 48
    B.5.3.2Town/ cityMunich
    B.5.3.3Post code81379
    B.5.3.4CountryGermany
    B.5.4Telephone number+4989 78080
    B.5.5Fax number+4989 7808267
    B.5.6E-mailHeiko.Rauer@daiichi-sankyo.eu
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Lixiana 30 mg film-coated tablets
    D.2.1.1.2Name of the Marketing Authorisation holderDaiichi Sankyo Europe GmbH
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameedoxaban
    D.3.2Product code DU-176b
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNedoxaban
    D.3.9.1CAS number 480449-70-5
    D.3.9.4EV Substance CodeSUB32701
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number30
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Lixiana 60 mg film-coated tablets
    D.2.1.1.2Name of the Marketing Authorisation holderDaiichi Sankyo EUrope GmbH
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameedoxaban
    D.3.2Product code DU-176b
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNedoxaban
    D.3.9.1CAS number 480449-70-5
    D.3.9.4EV Substance CodeSUB32701
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number60
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Sintrom - Tabletten
    D.2.1.1.2Name of the Marketing Authorisation holderMerus Labs Luxco II S.a R.L.
    D.2.1.2Country which granted the Marketing AuthorisationAustria
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameacenocumarol
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNacenocumarol
    D.3.9.1CAS number 152-72-7
    D.3.9.4EV Substance CodeSUB05211MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number4
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 4
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Phenoprogamma 3
    D.2.1.1.2Name of the Marketing Authorisation holderWorwag Pharma GmbH and Co. KG
    D.2.1.2Country which granted the Marketing AuthorisationGermany
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namephenprocoumon
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNphenprocoumon
    D.3.9.1CAS number 435-97-2
    D.3.9.4EV Substance CodeSUB09781MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number3
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 5
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Previscan 20 mg, comprime quadrisecable
    D.2.1.1.2Name of the Marketing Authorisation holderMERCK SANTE
    D.2.1.2Country which granted the Marketing AuthorisationFrance
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namefluindione
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNfluindione
    D.3.9.1CAS number 957-56-2
    D.3.9.4EV Substance CodeSUB07692MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 6
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Warfarin Teva 1 mg Tablets
    D.2.1.1.2Name of the Marketing Authorisation holderSun Pharmaceutical Industries Europe B.V.
    D.2.1.2Country which granted the Marketing AuthorisationIreland
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namewarfarin sodium
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNwarfarin sodium
    D.3.9.1CAS number CAS 129-06-6
    D.3.9.4EV Substance CodeSUB05128MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 7
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Warfarin Teva 2.5 mg Tablets
    D.2.1.1.2Name of the Marketing Authorisation holderSun Pharmaceutical Industries Europe B.V.
    D.2.1.2Country which granted the Marketing AuthorisationIreland
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namewarfarin sodium
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNwarfarin sodium
    D.3.9.1CAS number CAS 129-06-6
    D.3.9.4EV Substance CodeSUB05128MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number2.5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 8
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Lixiana 15 mg film-coated tablets
    D.2.1.1.2Name of the Marketing Authorisation holderDaiichi Sankyo Europe GmbH
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameedoxaban
    D.3.2Product code DU-176b
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNedoxaban
    D.3.9.1CAS number 480449-70-5
    D.3.9.4EV Substance CodeSUB32701
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number15
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Subjects undergoing catheter ablation of non-valvular
    atrial fibrillation
    Pacientes que se someten a ablación con catéter de la fibrilación auricular no valvular
    E.1.1.1Medical condition in easily understood language
    Subjects undergoing catheter ablation of non-valvular
    atrial fibrillation
    Pacientes que se someten a ablación con catéter de la fibrilación auricular no valvular
    E.1.1.2Therapeutic area Diseases [C] - Cardiovascular Diseases [C14]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 19.1
    E.1.2Level PT
    E.1.2Classification code 10003658
    E.1.2Term Atrial fibrillation
    E.1.2System Organ Class 10007541 - Cardiac disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Primary efficacy objective:
    To compare descriptively the incidence of the composite of all-cause death, stroke (ischemic, hemorrhagic, or undetermined) and Major Bleeding (International Society on Thrombosis and Hemostasis [ISTH] definition) in the edoxaban group against the vitamin K antagonist (VKA) group in subjects undergoing catheter ablation of atrial fibrillation (AF) in the period from the end of the catheter ablation procedure to Day 90/end-of-treatment (EOT).
    Primary safety objective:
    To compare descriptively the incidence of Major Bleeding (ISTH definition) in the edoxaban group against the VKA group in the period from date of first intake of study medication to Day 90/EOT.
    Objetivo principal de eficacia:
    Comparar de forma descriptiva la incidencia de la combinación de muerte por cualquier causa, ictus (isquémico, hemorrágico o indeterminado) y hemorragia mayor (definición de la International Society on Thrombosis and Hemostasis [Sociedad Internacional de Trombosis y Hemostasia; ISTH, por su siglas en inglés]) en el grupo de edoxabán frente al grupo de antagonistas de la vitamina K (AVK) en pacientes que se someten a ablación con catéter de la fibrilación auricular (FA) en el periodo comprendido entre el final del procedimiento de ablación con catéter y el día 90/fin de tratamiento (FdT).
    Objetivo principal de seguridad:
    Comparar de forma descriptiva la incidencia de hemorragia mayor (definición de la ISTH) en el grupo de edoxabán frente al grupo de AVK en el periodo comprendido entre la fecha de la primera toma del medicamento del estudio y el día 90/FdT.
    E.2.2Secondary objectives of the trial
    -Composite of all-cause death, stroke (ischemic, hemorrhagic, or undetermined, according to alternative definition (see Protocol Section 7.4.2) and Major Bleeding [ISTH]
    -Composite of stroke , SEE, CV mortality
    -Composite of stroke, SEE, and all-cause mortality
    -Composite of stroke and TIA
    -Stroke
    -SEE
    -TIA
    -Fatal stroke
    -Non-fatal stroke
    -Disabling stroke
    -Non-disabling stroke

    -Major Bleeding, Bleeding Academic Research Consortium [BARC] (2 or higher))
    -Major and Clinically Relevant Non-Major (CRNM) Bleeding
    -CRNM Bleeding
    -Minor Bleeding
    -Any Bleeding
    -Intracranial hemorrhage (ICH)
    -Life-threatening bleeding
    -Fatal Major Bleeding
    -Non-fatal Major Bleeding
    -Fatal Major Bleeding (defined by TIMI, BARC [2 or higher])
    -Non-fatal Major Bleeding (defined by TIMI, BARC [2 or higher])
    -AEs, SAEs, laboratory parameters, electrocardiogram and vital signs

    -Relevant Health Economics Outcome Research
    -Cardiac and anticoagulation markers
    Combinación de muerte por cualquier causa, ictus (isquémico, hemorrágico o indeterminado, según una definición alternativa (ver protocolo 7.4.2) y hemorragia mayor (ISTH)
    Combinación de ictus, AES, mortalidad cardiovascular CV
    Combinacion de ictus, AES, y mortalidad por cualquier causa
    Combinación de ictus y AIT
    Ictus
    AES
    AIT
    Ictus mortal
    Ictus no mortal
    Ictus discapacitante
    Ictus no discapacitante
    Hemorragia mayor,consorcio investigación hemorragia BARC, 2 o más
    Hemorragia no mayor clínicamente relevante ISTH
    ISTH Hemorragia
    Hemorragia menor
    Cualquier hemorragia
    Hemorragia intracraneal (HIC)
    Hemorragia potencialmente mortal
    Hemorragia mayor mortal
    Hemorragia mayor mortal (definida según TIMI y BARC [2 o más]
    Hemorragia mayor no mortal (definida según TIMI y BARC [2 o más]
    AA, AAG, parámetros laboratorio,electrocardiograma,constantes vitales
    Parámetros relevantes de investigación resultados económicos de salud
    Marcadores cardiacos y anticoagulación
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Male or female at least 18 years of age with documented history of paroxysmal (lasting ≤7 days), persistent (lasting >7 days but ≤12 months) or long-standing [long-lasting] persistent (>12 months) non-valvular AF. Duration of AF can be confirmed by any electrical tracing or a recording in the subject’s medical records (e.g., medical chart, hospital discharge summary).
    2. Subject is eligible and is scheduled for either radiofrequency (RF) or cryoballoon catheter ablation (both first and repeated procedure included).
    3. Signed ICF.
    1. Hombres y mujeres de al menos 18 años con antecedentes documentados de FA no valvular paroxística (que dura ≤7 días), persistente (que dura >7 días pero ≤12 meses) o persistente prolongada [de larga duración] (>12 meses). La duración de la FA se puede confirmar por medio de cualquier trazado eléctrico o un registro en la historia clínica del paciente (p. ej., anamnesis, informe de alta hospitalario).
    2. Pacientes aptos y que tienen programada una ablación con catéter de radiofrecuencia (RF) o crioablación con balón (se incluyen el primer procedimiento y los procedimientos repetidos).
    3. Consentimiento informado (CI) firmado.
    E.4Principal exclusion criteria
    1.AF considered to be of a transient or reversible nature (such as in myocarditis, post-surgery, ionic disturbances, thyrotoxicosis, pneumonia, severe anemia etc.).
    2.Subject post stroke, or with a systemic thromboembolic event within the past 6 months prior to randomization.
    3.Subject has a thrombus in the left atrial appendage (LAA), left atrium (LA), left ventricle (LV), or aorta, or an intracardial mass.
    4.Subject had a myocardial infarction (MI) within the 2 months prior to randomization or coronary artery bypass graft (CABG) surgery within 3 months prior to the randomization.
    5.Subject has signs of bleeding, history of clinically-relevant bleeding according to ISTH, or conditions associated with high risk of bleeding such as past history of intracranial
    (spontaneous or traumatic), or spontaneous intraocular, spinal, retroperitoneal, or intra-articular bleeding; overt gastrointestinal (GI) bleeding or active ulcer within the previous year; recent severe trauma, major surgery, or deep organ biopsy; active infective endocarditis; uncontrolled hypertension (blood pressure [BP] above 170/100 mmHg); or hemorrhagic disorder including known or suspected hereditary or acquired bleeding or coagulation disorder in the last 12 months prior to randomization.
    6. Subjects with mechanical heart valves, subjects with moderate to severe mitral stenosis and subjects who have new implantation (within 3 months prior to randomization) of a bioprosthetic heart valve, with or without AF.
    7. Subjects with a history of LAA occlusion/exclusion (either by surgery or by a procedure).
    8. Subjects with any contraindication for edoxaban, VKA, low molecular weight heparin (LMWH), heparin therapy.
    9. Subjects receiving dual antiplatelet therapy (DAPT, i.e., aspirin and P2Y12 antagonist) or planned to receive DAPT during the study
    10. Subjects who require chronic use of medicines affecting hemostasis such as higher doses of aspirin (acetylsalicylic acid [ASA]) (ASA up to 100 mg per day allowed) or chronic oral or parenteral intake of non-aspirin non-steroidal anti inflammatory drugs (NSAID) on ≥4 days/week (use of NSAIDs via other routes is not restricted)
    11. Subjects with active liver disease or persistent (confirmed by repeat assessments at least a week apart) elevation of liver enzymes/bilirubin:
    ― Alanine transaminase (ALT) or aspartate transaminase (AST) ≥2 times the upper limit of normal (ULN)
    ― Total bilirubin (TBL) ≥1.5 times the ULN (subjects whose elevated TBL is due to known Gilbert’s syndrome may be included in the study)
    ― Hepatic disease associated with coagulopathy and clinically relevant bleeding risk.
    12. Subjects with kidney failure (calculated creatinine clearance [CrCL] <15 mL/min).
    13. Subjects with hemoglobin <10 g/dL or platelet count <100,000 cells/µL or white blood cell (WBC) count <3000 cells/µL.
    14. Subjects with pre-planned invasive diagnostic or therapeutic procedures/interventions (other than endoscopy) during the study period in which bleeding is anticipated.
    15. Participation in any other interventional trial (subjects who received any investigational drug or device within 30 days prior to randomization, or plan to receive such investigational therapy during the study period).
    16. Previous randomization in this study.
    17. Female subjects of childbearing potential without using adequate contraception (female of childbearing potential is defined as one who has not been postmenopausal for at least one year, or has not been surgically sterilised, or has not had a hysterectomy at least 3 months prior to the start of this study [Visit 1]). Females taking oral contraceptives
    should have been on therapy for at least 3 months. Adequate contraceptives include hormonal intra-uterine devices, hormonal contraceptives (oral, depot, patch or injectable), and double barrier methods such as condoms or diaphragms with spermicidal gel or foam.
    18. Pregnant or breast-feeding subjects.
    19. Subjects with the following diagnoses or situations:
    - Active cancer undergoing chemotherapy, radiation or major surgery within the next 5 months
    - Significant active/uncontrolled concurrent medical illness
    - Life expectancy <6 months.
    20. Subjects who are unlikely to comply with the protocol (e.g., uncooperative attitude, inability to return for subsequent visits, and/or otherwise considered by the Investigator to be unlikely to complete the study).
    21. Subjects with a known drug or alcohol dependence within the past 12 months prior to randomization as judged by the Investigator.
    22. Subjects with any condition that, in the opinion of the Investigator, would place the subject at increased risk of harm if he/she participated in the study.
    23. Planned procedure using laser catheter ablation or other forms of catheter ablation different from RF or cryoballoon (i.e. high intensity focused ultrasound [HIFU], microwaves, hot balloon, etc)
    1.FA considerada de naturaleza transitoria o reversible ( iocarditis, tras una cirugía, trastornos electrolíticos, tirotoxicosis, neumonía, anemia grave, etc.)
    2.Pte.después de un ictus, o con un acontecimiento tromboembólico sistémico en los 6 m. ant.a la aleatorización
    3.Pte.con un trombo en el apéndice auricular izq. (AAI), la aurícula izq.(AI), el ventrículo izq. (VI), o la aorta, o una masa intracardiaca
    4.Pte.con infarto de miocardio (IM) en los 2 meses ante. a la aleatorización o una cirugía de derivación aortocoronaria (CABG) en los 3 m.anteriores a la aleatorización
    5.Pte.con signos hemorragia, antecedentes de hemorragia clínicamente relevante de acuerdo con la ISTH, o afecciones asociadas a un alto riesgo de hemorragia como antecedentes de hemorragia intracraneal (espontánea o traumática), o hemorragia espontánea intraocular, espinal, retroperitoneal o intraarticular; hemorragia gastrointestinal (GI) evidente o úlcera activa el año anterior;traumatismo grave reciente, cirugía mayor o biopsia de un órgano profundo; endocarditis infecciosa activa; hipertensión no controlada (tensión arterial [TA] superior a 170/100 mmHg);o trastorno hemorrágico, incluido un trastorno hemorrágico o de coagulación hereditario o adquirido, conocido o sospechoso, en los 12 meses ant. a aleatorización
    6.Pte. válvulas cardiacas mecánicas, pacientes con estenosis mitral de moderada a grave y pacientes con implante reciente de una válvula cardiaca bioprotésica (en los 3 meses anteriores a la aleatorización), con o sin FA.
    7.Pte.con antecedentes de inclusión/exclusión del apén. auricular izq. (mediante cirugía o mediante un proced.)
    8.Pte.con contraindicaciones para el tratamiento con edoxabán, AVK, heparina de bajo peso molecular o heparina
    9.Pte.que reciben antiplaquetario dual (TAPD, aspirina y un antagonista de P2Y12) o tienen previsto recibir un trat. antiplaquetario dual durante el estudio.
    10.Pte.requieren el uso crónico de medicamentos afectan a la hemostasia, tales como dosis más altas de aspirina (ácido acetilsalicílico [ASA]) (está permitido el uso de ASA a dosis de hasta 100 mg al día) o uso oral o parenteral crónico de antiinflamatorios no esteroideos (AINE) que no contengan aspirina ≥4 días/semana (no se limita el uso de AINE administrados por otras vías)
    11.Pte.enfermedad hepática activa o aumento (confirmado en análisis repetidos con un intervalo mínimo de una semana) de las enzimas hepáticas/bilirrubina:
    Alanina-aminotransferasa (ALAT) o aspartato-aminotransferasa (ASAT) ≥2 veces el límite superior de la normalidad (LSN)
    Bilirrubina total (BT) ≥1,5 veces el LSN (se puede incluir a pacientes con aumentos de la bilirrubina total que se sabe que son debidos al síndrome de Gilbert)
    Enfermedad hepática asociada a coagulopatía y riesgo de hemorragia clínicamente relevante
    12.Pte.con insuficiencia renal (aclaramiento de creatinina [CrCL] calculado <15 ml/min)
    13.Pte.con hemoglobina <10 g/dl o recuento de plaquetas <100 000 células/µl o recuento de leucocitos <3000 células/µl
    14.Pte.con intervenciones o procedimientos diagnósticos o terapéuticos invasivos previamente programados (excepto endoscopia) durante el periodo del estudio espera hemorragia.
    15.Participación en cualquier ensayo intervencionista (pacientes que recibieron algún medicamento o dispositivo en investigación en los 30 días anteriores a la aleatorización, o que tienen previsto recibir dicho tratamiento en investigación durante estudio)
    16.Aleatorización previa en este estudio
    17.Mujeres fértiles no utilizan anticonceptivos (mujer fértil aquella que no lleva al menos un año posmenopáusica, o que no está quirúrgicamente esterilizada, o que no se ha sometido a una histerectomía al menos 3 meses antes de comenzar este estudio [visita 1]). Las mujeres q.toman anticonceptivos orales deben llevar 3 meses recibiendo el tratamiento. Los anticonceptivos adecuados incluyen los dispositivos intrauterinos hormonales, los anticonceptivos hormonales (orales, de liberación lenta, parches o inyectables) y métodos de doble barrera preservativos o diafragmas con gel o espuma espermicida
    18.Mujeres embarazadas o en periodo de lactancia
    19.Pte. con los siguientes diagnósticos o en las siguientes situaciones:Cáncer activo en tratamiento con quimioterapia, radiación o cirugía mayor en los próximos 5 m.
    Enfermedad médica simultánea activa/no controlada.Esperanza de vida <6 meses.
    20.Pte.con baja probabilidad de cumplir con el protocolo (p. ej., actitud no cooperativa, incapacidad acudir visitas y/o por otro motivo, el investigador poco probable completen el estudio).
    21.Pte.drogodependientes o alcoholismo en los 12 meses ant. aleat.
    22.Pte.con cualquier afección que investigador, que el paciente corriera mayor riesgo de sufrir daños.
    23.Proced. programado ablación con catéter de láser u otras formas de ablación con catéter que no sean RF o crioablación con balón (ultrasonido focalizado de alta intensidad [HIFU], microondas, balón caliente, etc.)
    E.5 End points
    E.5.1Primary end point(s)
    Composite of all-cause death, stroke (ischemic, hemorrhagic, or undetermined), and Major Bleeding (ISTH definition), analyzed as time to first occurrence of any component.

    Major Bleeding (ISTH definition), analyzed as time to first occurrence of Major Bleeding.
    Combinación de muerte por cualquier causa, ictus (isquémico, hemorrágico o indeterminado) y hemorragia mayor (ISTH), analizada como el tiempo hasta la primera aparición de cualquiera de los componentes

    Hemorragia mayor (ISTH), analizada como el tiempo hasta la primera aparición de hemorragia mayor
    E.5.1.1Timepoint(s) of evaluation of this end point
    All adjudicated endpoints are analyzed as time to first occurrence of any of its components
    Todas las variables adjudicadas se analizan como el tiempo hasta la primera aparición de cualquiera de sus componentes
    E.5.2Secondary end point(s)
    Efficacy:
    • Composite of all-cause death, stroke (ischemic, hemorrhagic, or undetermined, according to alternative definition (see Protocol Section 7.4.2 for details) and Major Bleeding (ISTH definition)
    • Composite of stroke (ischemic, hemorrhagic, or undetermined) SEE, and CV mortality
    • Composite of stroke (ischemic, hemorrhagic, or undetermined) SEE, and all-cause mortality
    • Composite of stroke (ischemic, hemorrhagic, or undetermined) and TIA
    • Stroke (ischemic, hemorrhagic, or undetermined)
    • Stroke (ischemic)
    • Stroke (hemorrhagic)
    • Stroke (undetermined)
    • SEE
    • TIA
    • Fatal stroke (ischemic, hemorrhagic, or undetermined)
    • Non-fatal stroke (ischemic, hemorrhagic, or undetermined)
    • Disabling stroke (ischemic, hemorrhagic, or undetermined)
    • Non-disabling stroke (ischemic, hemorrhagic, or undetermined)
    Safety:
    • Major Bleeding (defined by TIMI, BARC (2 or higher))
    • Major and Clinically Relevant Non-Major (CRNM) Bleeding (ISTH definition)
    • CRNM Bleeding (ISTH definition)
    • Minor Bleeding (ISTH definition)
    • Any Bleeding
    • ICH
    • Life-threatening bleeding
    • Fatal Major Bleeding (ISTH definition)
    • Non-fatal Major Bleeding (ISTH definition)
    • Fatal Major Bleeding (defined by TIMI, BARC [2 or higher])
    • Non-fatal Major Bleeding (defined by TIMI, BARC [2 or higher])
    • Safety parameters such as AEs, SAEs, laboratory parameters, ECG and vital signs.
    Eficacia
    • Combinación de muerte por cualquier causa, ictus (isquémico, hemorrágico o indeterminado, según una definición alternativa ver Protocolo 7.4.2) ) y hemorragia mayor (definición de la ISTH)
    • Combinación de ictus (isquémico, hemorrágico o indeterminado), AES y mortalidad CV
    • Combinación de ictus (isquémico, hemorrágico o indeterminado), AES y mortalidad por cualquier causa
    • Combinación de ictus (isquémico, hemorrágico o indeterminado) y AIT
    • Ictus (isquémico, hemorrágico o indeterminado)
    • Ictus (isquémico)
    • Ictus (hemorrágico)
    • Ictus (indeterminado)
    • AES
    • AIT
    • Ictus mortal (isquémico, hemorrágico o indeterminado)
    • Ictus no mortal (isquémico, hemorrágico o indeterminado)
    • Ictus discapacitante (isquémico, hemorrágico o indeterminado
    • Ictus no discapacitante (isquémico, hemorrágico o indeterminado)
    Seguridad
    • Hemorragia mayor (definida como TIMI, BARC (2 o más )
    • Hemorragia mayor y hemorragia no mayor clínicamente relevante (definición de la ISTH)
    • Hemorragia no mayor (definición de la ISTH)
    • Hemorragia menor (definición de la ISTH)
    • Cualquier hemorragia
    • (HIC)
    • Parámetros relevantes de la investigación de resultados económicos de la salud
    • Hemorragia mayor mortal (definición de la ISTH)
    • Hemorragia mayor mortal (definida según TIMI, BARC [2 o más])
    • Hemorragia mayor no mortal (definida según TIMI, BARC [2 o más])
    • Parámetros de seguridad tales como AA, AAG, parámetros de laboratorio, ECG y constantes vitales
    E.5.2.1Timepoint(s) of evaluation of this end point
    All adjudicated endpoints are analyzed as time to first occurrence of any of its components
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic Yes
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned4
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA65
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Belgium
    Canada
    Czech Republic
    France
    Germany
    Hungary
    Italy
    Korea, Republic of
    Netherlands
    Poland
    Spain
    Taiwan
    United Kingdom
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    All randomized subjects will have a contact planned 30-35 days after the EOT visit, to collect data on targeted concomitant medications, SAEs, and other AESI. The final contact is the post-treatment follow-up visit scheduled at 30-35 days after the EOT visit. The study is deemed completed as soon as the final contact of the last subject is performed in all centers and in all participating countries.
    Habrá un contacto planeado con sujetos aleatorizados entre 30-35 días después de Visita de Fin de Ensayo, para recopilar datos de medicaciones concomitantes específicas, A. A. Graves y otros A.A. de Especial Interés. El último contacto es visita de Seguimiento post-tratamiento programada entre 30-35 días después de visita de Fin de Ensayo. El Ensayo se considerará finalizado se haya llevado a cabo el contacto final del último paciente en todos los centros y en todos los países participantes.  
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 260
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 300
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state33
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 486
    F.4.2.2In the whole clinical trial 560
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2017-05-03
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2017-04-11
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2018-09-24
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2021 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA